Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,351 matching trials from the live ClinicalTrials.gov search.

Filters: New Haven, Connecticut Clear all

Conditions: Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions: Pembrolizumab, Stereotactic Body Radiation Therapy; Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 254
States / cities: Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 638
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more

Conditions: Healthy Volunteers
Interventions: Glasdegib, High Fat, High Calorie Meal, Rabeprazole; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: COVID-19 Pneumonia
Interventions: Tofacitinib 10 mg, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Participants
Interventions: PF-06954522, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Malignant Neoplasm
Interventions: Patritumab Deruxtecan; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Ventricular Arrhythmias
Interventions: Implantation of subcutaneous ICD, Implantation of transvenous ICD; Device
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Other
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: enzalutamide, abiraterone, prednisone; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 527
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 382 more

Conditions: Pain Management, Postoperative Pain
Interventions: PCDD Generation 1 system; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Intellectual Disability, Perceptual Disorders, Memory Disorders
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Months to 13 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more

Conditions: Appendicitis
Interventions: transvaginal appendectomy; Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Aortic Valve Stenosis
Interventions: Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 2,223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 61
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Medical Chart Review; Procedure · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 2,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 630
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more

Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions: Surgery, Preoperative chemotherapy; Procedure · Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 116
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions: Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Procedure · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 370
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more

Conditions: Previously Treated Non-Small Cell Lung Cancer
Interventions: Screening Platform; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1229
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 807 more

Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions: Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 55
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 42 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 838
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more

Conditions: Menopausal Women
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hyperoxia
Interventions: 60% oxygen, 100% oxygen; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Prevention, STI Prevention
Interventions: One Night Stan Prototype; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Carcinoma, Renal Cell
Interventions: Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Vibostolimab/Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 6 more

Search by objective public record fields.

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

Tofacitinib for Treatment of Moderate COVID-19

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

PCDD Generation 1 Oral Liquid Acetaminophen Delivery Evaluation

Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood

Transvaginal Appendectomy

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death

The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy

Formative Research for an HIV Videogame for Young Black Women

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)